Initial Statement of Beneficial Ownership (3)
August 15 2019 - 3:03PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Caligan Partners LP
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
8/12/2019
|
3. Issuer Name
and
Ticker or Trading Symbol
AMAG PHARMACEUTICALS, INC. [AMAG]
|
(Last)
(First)
(Middle)
520 MADISON AVENUE
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
___
X
___ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Street)
NEW YORK, NY 10022
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock, par value $0.01 per share
|
3499428
|
I
|
See footnote
(1)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(1)
|
This Form 3 is filed by Caligan Partners LP ("Caligan"), David Johnson and Samuel J. Merksamer, with respect to the securities held by an affiliated fund and managed account to which Caligan serves as investment manager. David Johnson and Samuel J. Merksamer are each a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
|
Remarks:
Remarks: Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 3 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Caligan Partners LP
520 MADISON AVENUE
NEW YORK, NY 10022
|
|
X
|
|
|
MERKSAMER SAMUEL J.
520 MADISON AVENUE
NEW YORK, NY 10022
|
|
X
|
|
|
JOHNSON DAVID EDWARD
520 MADISON AVENUE
NEW YORK, NY 10022
|
|
X
|
|
|
Signatures
|
Caligan Partners LP, By: /s/ Samuel J. Merksamer, Partner
|
|
8/15/2019
|
**
Signature of Reporting Person
|
Date
|
/s/ David Johnson
|
|
8/15/2019
|
**
Signature of Reporting Person
|
Date
|
/s/ Samuel J. Merksamer
|
|
8/15/2019
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Apr 2023 to Apr 2024